Expertise in
2
conditions

Dr. Bruce Averbook

Surgical Oncology
The MetroHealth System
2500 Metrohealth Dr, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
The MetroHealth System
2500 Metrohealth Dr, 
Cleveland, OH 

Overview

Bruce Averbook is a Surgical Oncologist in Cleveland, Ohio. Dr. Averbook is highly rated in 2 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, Tissue Biopsy, and Endoscopy.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 66 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Surgical Oncology

Licenses

Surgery in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

The MetroHealth System
2500 Metrohealth Dr, Cleveland, OH 44109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

66 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Staging breast cancer by sentinel lymph node biopsy: Do patients with a single negative sentinel node (N=1) experience worse outcomes than those with multiple negative sentinel nodes (N>1)?
Staging breast cancer by sentinel lymph node biopsy: Do patients with a single negative sentinel node (N=1) experience worse outcomes than those with multiple negative sentinel nodes (N>1)?
Journal: Surgical oncology
Published: February 21, 2018
Similar Doctors
Peter Rose
Expertise in
20
conditions
Dr. Peter Rose
Surgical Oncology
Expertise in
20
conditions
Dr. Peter Rose
Surgical Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (5.1 miles away)
866-223-8100
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Rose is a Surgical Oncologist in Cleveland, Ohio. Dr. Rose has been practicing medicine for over 49 years is highly rated in 20 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Hernia Surgery.

Expertise in
15
conditions
Dr. Jordan Winter
Surgical Oncology | General Surgery
Expertise in
15
conditions
Dr. Jordan Winter
Surgical Oncology | General Surgery

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (5.7 miles away)
216-844-5777
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jordan Winter is a Surgical Oncologist and a General Surgeon in Cleveland, Ohio. Dr. Winter is highly rated in 15 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
20
conditions
Dr. Chad Michener
Surgical Oncology
Expertise in
20
conditions
Dr. Chad Michener
Surgical Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (5.1 miles away)
866-223-8100
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chad Michener is a Surgical Oncologist in Cleveland, Ohio. Dr. Michener has been practicing medicine for over 33 years is highly rated in 20 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Endoscopy, and Hernia Surgery.

Frequently Asked Questions about Dr. Bruce Averbook

How do I make an appointment with Dr. Bruce Averbook?

You can book an appointment with Dr. Bruce Averbook by calling their office at 216-778-7800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bruce Averbook a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bruce Averbook is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bruce Averbook specialize in?

While Dr. Bruce Averbook is a Surgical Oncology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Bruce Averbook participate in research or clinical trials?

Yes. Dr. Bruce Averbook has published 8 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Bruce Averbook's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bruce Averbook accept my insurance?

Dr. Bruce Averbook accepts most major insurance plans, including CareSource and Humana. We recommend calling the office directly at 216-778-7800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Averbook's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile